Market closed
Pacira BioSciences/$PCRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pacira BioSciences
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Ticker
$PCRX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
789
Website
PCRX Metrics
BasicAdvanced
$1.1B
-
-$2.15
0.86
-
Price and volume
Market cap
$1.1B
Beta
0.86
52-week high
$31.67
52-week low
$11.16
Average daily volume
817K
Financial strength
Current ratio
2.404
Quick ratio
1.931
Long term debt to equity
55.013
Total debt to equity
82.078
Interest coverage (TTM)
5.89%
Management effectiveness
Return on assets (TTM)
3.90%
Return on equity (TTM)
-12.08%
Valuation
Price to revenue (TTM)
1.497
Price to book
1.35
Price to tangible book (TTM)
2.98
Price to free cash flow (TTM)
5.87
Growth
Revenue change (TTM)
3.85%
Earnings per share change (TTM)
-342.91%
3-year revenue growth (CAGR)
8.98%
3-year earnings per share growth (CAGR)
32.76%
What the Analysts think about PCRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pacira BioSciences stock.
PCRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PCRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PCRX News
AllArticlesVideos
Pacira BioSciences: Back On An Uptrend After Positive Developments
Seeking Alpha·1 hour ago
Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
Accesswire·2 hours ago
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
GlobeNewsWire·3 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pacira BioSciences stock?
Pacira BioSciences (PCRX) has a market cap of $1.1B as of March 14, 2025.
What is the P/E ratio for Pacira BioSciences stock?
The price to earnings (P/E) ratio for Pacira BioSciences (PCRX) stock is 0 as of March 14, 2025.
Does Pacira BioSciences stock pay dividends?
No, Pacira BioSciences (PCRX) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Pacira BioSciences dividend payment date?
Pacira BioSciences (PCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Pacira BioSciences?
Pacira BioSciences (PCRX) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.